Your browser is no longer supported. Please, upgrade your browser.
Settings
ESPR [NASD]
Esperion Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.48 Insider Own0.70% Shs Outstand26.88M Perf Week6.02%
Market Cap767.24M Forward P/E- EPS next Y-3.16 Insider Trans108.14% Shs Float26.11M Perf Month-12.42%
Income-143.60M PEG- EPS next Q-2.22 Inst Own- Short Float36.57% Perf Quarter-2.29%
Sales227.50M P/S3.37 EPS this Y-45.70% Inst Trans-1.77% Short Ratio11.18 Perf Half Y-21.28%
Book/sh-3.58 P/B- EPS next Y67.60% ROA-51.50% Target Price- Perf Year-46.02%
Cash/sh11.54 P/C2.52 EPS next 5Y16.90% ROE- 52W Range23.90 - 56.10 Perf YTD11.69%
Dividend- P/FCF- EPS past 5Y-18.20% ROI-145.70% 52W High-48.24% Beta1.23
Dividend %- Quick Ratio3.50 Sales past 5Y- Gross Margin98.90% 52W Low21.51% ATR2.28
Employees479 Current Ratio3.70 Sales Q/Q860.00% Oper. Margin-53.40% RSI (14)49.03 Volatility5.72% 6.89%
OptionableYes Debt/Eq- EPS Q/Q-71.80% Profit Margin-63.10% Rel Volume0.94 Prev Close27.46
ShortableYes LT Debt/Eq- EarningsFeb 23 AMC Payout- Avg Volume853.69K Price29.04
Recom2.40 SMA20-3.21% SMA50-1.45% SMA200-17.46% Volume805,355 Change5.75%
Feb-12-21Downgrade Jefferies Buy → Hold $30
Feb-09-21Downgrade Goldman Neutral → Sell $44 → $24
Jan-15-21Downgrade BofA Securities Buy → Neutral $52 → $35
Nov-10-20Upgrade Credit Suisse Neutral → Outperform $45
Sep-29-20Resumed JP Morgan Underweight $35
Aug-11-20Downgrade Credit Suisse Outperform → Neutral $83 → $45
Apr-01-20Resumed BofA/Merrill Buy $50
Mar-17-20Upgrade Citigroup Neutral → Buy
Feb-24-20Downgrade Northland Capital Outperform → Market Perform $60
Feb-14-20Downgrade Citigroup Buy → Neutral $82
Sep-16-19Upgrade Goldman Sell → Neutral $55 → $45
May-29-19Downgrade Goldman Neutral → Sell
May-06-19Upgrade BofA/Merrill Underperform → Neutral
Apr-26-19Upgrade Goldman Sell → Neutral $50
Mar-13-19Upgrade JP Morgan Underweight → Neutral $38 → $47
Jan-07-19Reiterated Needham Strong Buy $94 → $114
Dec-13-18Initiated Goldman Sell $45
Oct-29-18Upgrade Northland Capital Market Perform → Outperform
Oct-16-18Initiated BTIG Research Buy $82
Aug-17-18Upgrade Citigroup Neutral → Buy
Feb-26-21 11:55AM  
Feb-24-21 03:02AM  
Feb-23-21 05:15PM  
04:01PM  
02:30PM  
Feb-17-21 02:25AM  
Feb-09-21 08:00AM  
Feb-03-21 11:49AM  
02:55AM  
Jan-29-21 05:21PM  
05:00PM  
Jan-14-21 10:36AM  
Jan-13-21 01:21PM  
06:27AM  
Jan-04-21 11:53AM  
Dec-21-20 08:00AM  
Dec-19-20 02:45AM  
Dec-16-20 05:34PM  
03:00AM  
Dec-15-20 07:00AM  
Dec-02-20 12:37PM  
11:30AM  
Nov-13-20 09:15AM  
Nov-12-20 06:17AM  
Nov-10-20 04:30PM  
Nov-06-20 05:00PM  
Nov-04-20 06:15AM  
Nov-03-20 09:36AM  
Nov-02-20 11:31PM  
05:15PM  
04:49PM  
04:01PM  
02:30PM  
Oct-27-20 08:00AM  
Oct-26-20 12:31PM  
Oct-19-20 08:00AM  
Oct-13-20 03:04PM  
Oct-07-20 08:00AM  
Sep-28-20 04:06PM  
Sep-22-20 08:56AM  
Sep-02-20 08:41AM  
Aug-26-20 09:07AM  
Aug-21-20 04:05PM  
Aug-11-20 11:10AM  
02:30AM  
Aug-10-20 05:15PM  
04:04PM  
Aug-07-20 09:27AM  
Aug-06-20 10:05AM  
Aug-03-20 07:26AM  
Jul-16-20 07:16PM  
Jul-01-20 11:12AM  
Jun-23-20 11:42AM  
Jun-22-20 07:00AM  
Jun-16-20 03:09PM  
Jun-14-20 09:30AM  
Jun-12-20 10:20AM  
07:19AM  
Jun-08-20 08:00AM  
Jun-05-20 11:31AM  
Jun-04-20 12:00PM  
07:00AM  
May-27-20 08:00AM  
May-15-20 06:00PM  
May-08-20 02:49PM  
May-07-20 11:47AM  
09:01AM  
08:00AM  
May-06-20 06:55PM  
04:05PM  
Apr-30-20 08:00AM  
Apr-21-20 07:01AM  
Apr-20-20 07:00AM  
Apr-18-20 10:59AM  
Apr-09-20 08:00AM  
Apr-07-20 10:43AM  
Apr-06-20 07:05AM  
07:00AM  
Apr-05-20 08:26AM  
Mar-30-20 04:15PM  
Mar-28-20 11:30AM  
09:30AM  
Mar-23-20 07:30AM  
Mar-18-20 07:30AM  
Feb-28-20 04:15PM  
08:12AM  
07:00AM  
Feb-27-20 10:15AM  
07:35AM  
07:00AM  
Feb-26-20 05:30PM  
Feb-21-20 04:38PM  
04:27PM  
Feb-16-20 03:03PM  
Feb-03-20 01:30PM  
Jan-31-20 07:02AM  
07:01AM  
Jan-27-20 12:20PM  
Jan-07-20 07:30AM  
Jan-03-20 04:15PM  
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MAYLEBEN TIMOTHY MPresident & CEODec 30Option Exercise2.1010,70022,427122,698Dec 31 04:09 PM
BIOTECH TARGET N V10% OwnerNov 03Buy25.31200,0005,062,1203,947,964Nov 04 04:37 PM
MAYLEBEN TIMOTHY MPresident & CEOMar 11Buy43.002,500107,500111,998Mar 12 07:34 AM